WWARN researchers have worked together with experts at Global Good-Intellectual Ventures Laboratory and the Queensland University of Technnology to produce a new tool designed to support researchers using microscopy in malaria research.

Recently the WWARN Pharmacology group and partners, published a study in the journal, Antimicrobial Agents and Chemotherapy. The study used PK/PD models to explore ways to enhance the efficacy of the commonly used antimalarial, artemether-lumefantrine (AL), in pregnant women and reduce the risk of t...

Pooled analysis identifies lumefantrine concentrations needed for curing malaria patients at highest risk

A new study from WWARN’s ACT Africa Baseline Study Group finds that current indicators of the efficacy of ACT based on persistence of parasites in the first 3 days after treatment may need some adjustment for African populations, due to the differences in immunity between African and Asian populati...

New report launched today by the WHO summarizes the remarkable progress seen, on a global and regional level, in reversing malaria mortality and incidence since 2000.

WWARN Scientific Director reviews new study published in the Proceedings of the National Academy of Sciences.

The WorldWide Antimalarial Resistance Network (WWARN) has been shortlisted for the 2015 Times Higher Education (THE) Award for the ‘International Collaboration of the Year’.

The 193 Member States of the United Nations have reached agreement on the outcome document that will constitute the new sustainable development agenda that will be adopted this September by world leaders.

The World Health Organization launches the technical brief 'Control and elimination of P. vivax malaria' in Delhi, India. This launch comes shortly after the Global Technical Strategy for Malaria (GTS) released at the World Health Assembly in May 2015.

Special supplement and live webcast event focuses on the major global threat of falsified and substandard medicines

Prof Joel Tarning, Head of the Pharmacometric Modelling Group at WWARN, has been awarded a prize for young researchers.

New guidelines help researchers undertaking systematic reviews and IPD meta-analyses to report their findings in a full and transparent manner.

The WWARN In Vitro Analysis and Reporting Tool (IVART) is now freely accessible to all researchers

Results from WWARN Dose Impact Study Groups have provided evidence for the revised recommendations for optimal use of artemisinin combination therapies included in the updated WHO ‘Guidelines for the Treatment of Malaria’

The Malaria in Pregnancy Library is a regularly updated, comprehensive bibliographic database of published and unpublished literature relating to malaria in pregnancy.

A new artesunate-mefloquine (AS-MQ) Dose Impact Study Group will investigate the tolerability of AS-MQ and the effects of mefloquine and artesunate mg/kg dosing.

Last week the World Health Assembly agreed a new global malaria strategy for 2016-2030 and approved the 2016-17 programme budget.

WWARN’s new ACT Malaria and Malnutrition Study Group is investigating the association between malnutrition in young children and the efficacy of antimalarial treatments. Find out how you can get involved.

Monitoring the potential emergence, spread and prevalence of K13 mutations associated with resistant parasites in other regions can provide us with an early warning system to trigger rapid public health mobilisation to drive eradication. The WWARN team has developed an interactive tool that collates...

A new microscopy manual is supporting researchers to deliver consistent and reliable data, as well as promoting standardisation in reports.